Bridge Medicines Enters Agreement with Memorial Sloan Kettering to Develop Kidney‐Specific Delivery Platform for the Treatment of Acute Kidney Injury

NEW YORK, NEW YORK – July 23, 2018

Bridge Medicines announced today an agreement with Memorial Sloan Kettering (MSK) to develop a platform designed to deliver drugs specifically to the kidney. The first disease target will be acute kidney injury (AKI), a highly prevalent and currently unmet medical need.